KRAS is one of the most frequently mutated oncogenes in cancer: Approximately 30 to 40% of patients with colorectal cancer harbor missense mutations in KRAS, and KRAS mutations have long been associated with increased tumor aggressiveness, resistance to treatment, and poor patient outcomes (42). This evidence concerns the gene KRAS and neoplasm.